Skip to main content

AyuVis Research, Inc.

Tuesday, February 27, 2024
AyuVis is pioneering novel small molecule immunotherapies to prevent/treat inflammatory and infectious diseases based on a platform technology of macrophage modulation for a balanced immune response. An IND has been approved by the FDA in Jan 2024 for the lead candidate, AVR-48, to initiate a Phase 1 HAV clinical trial. AVR-48 has been granted Orphan Drug and Rare Pediatric Disease Designations for the prevention of bronchopulmonary dysplasia in preterm infants. We are first targeting a rare disease for high impact and a faster path to commercialization. The Phase 1 will also apply to follow-on respiratory conditions with unmet need, including ARDS and ventilator-associated pneumonia. Validated in extensive preclinical research, these immunotherapies are proven safe, to prevent organ damage, promote new cell growth, reduce mortality, and eliminate MDR bacteria via phagocytosis. Other therapeutic areas that can be addressed include ocular, renal, skin, and complicated infections/sepsis.
suchismita Acharya, Founder & CEO - AyuVis Research, Inc.




United States


CEO/Top Company Official

Suchismita Acharya, PhD - CEO

Lead Product in Development

AVR-48, a small molecule immunotherapy

Development Phase of Primary Product

Phase I

Number Of Unlicensed Products

Six unlicensed assets

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.